Jpmorgan Chase & CO Design Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DSGN
# of Institutions
101Shares Held
31.5MCall Options Held
1.1KPut Options Held
21.3K-
Sr One Capital Management, LP6.53MShares$34.7 Million9.6% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$26.8 Million1.58% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$12.3 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.7MShares$9.02 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$7.88 Million0.61% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $297M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...